Page 7 of 23
OP9.2 | Diabetic Retinopathy — SDL Guide (Part 3)
Screening Protocol for Diabetic Retinopathy
A well-designed screening programme is the single most effective public health intervention for preventing blindness from diabetic retinopathy, because it detects treatable disease before any symptoms appear. The rationale for screening rests on a straightforward but often overlooked fact: the stages of DR most amenable to treatment — moderate and severe NPDR, and early PDR — are entirely asymptomatic, and by the time a patient notices visual deterioration, the opportunity for vision-preserving intervention may already have narrowed. The physician in primary or general medicine is therefore the pivotal link in this prevention chain: they manage the underlying diabetes, they know the patient's duration of disease and glycaemic history, and they are positioned to initiate and audit screening adherence. Failing to arrange regular fundoscopy for a diabetic patient is a clinical governance failure as significant as failing to check blood pressure. As a clinician managing diabetic patients, you are responsible for initiating and ensuring adherence to this protocol.
When to start screening:
- Type 1 DM: begin fundoscopy 5 years after diagnosis (retinopathy is rare in the first 5 years of T1DM in pre-pubertal patients). In adults with T1DM, screen from diagnosis.
- Type 2 DM: screen at the time of diagnosis, because T2DM may have been present for years before detection, and retinopathy may already be present at the time of DM diagnosis.
- During pregnancy: screen at booking and again in the third trimester (pregnancy can accelerate DR progression significantly; monthly review may be needed if DR is present).
Screening frequency (based on retinopathy grade):
| Retinopathy Grade | Screening Interval |
|---|---|
| No retinopathy | Annual |
| Mild NPDR | 6–12 monthly |
| Moderate NPDR | 3–6 monthly |
| Severe NPDR | 3 monthly — refer to ophthalmologist |
| PDR / CSME | Urgent referral — ophthalmologist-led care |
Screening method in India: the National Programme for Control of Blindness and Visual Impairment (NPCBVI) incorporates DR screening through digital fundus photography at district hospitals and through trained vision technicians at community health centres. Two-field (disc-centred and macula-centred) or wide-field photography is graded by trained graders or using AI-assisted software. Teleophthalmology networks extend screening to rural populations.
Referral criteria: refer to an ophthalmologist when any of the following are present — severe NPDR (4-2-1 rule), any PDR (any neovascularisation), CSME or DME on fundoscopy, any sudden visual loss, any pregnancy with DR.
Key message: screening only works if you actually perform it or arrange it. A diabetic patient who leaves your clinic without a fundus examination documented or planned is at avoidable risk.
CLINICAL PEARL
The NPDR vs PDR distinction is the single most important clinical decision point in diabetic retinopathy. Remember: NPDR = changes within the existing vessels (microaneurysms, haemorrhages, exudates, IRMA, venous beading) — NO new vessels. The moment you see any new vessel growth — on the disc (NVD) or on the retina (NVE) — the patient has crossed into PDR and requires urgent referral for PRP or anti-VEGF. A common trap: IRMA (intraretinal microvascular abnormalities in severe NPDR) can be mistaken for NVE. The distinction: IRMA is confined within the retinal layers, does not leak on FFA, and does not cross over vessels; NVE grows on the retinal surface, projects into the vitreous, leaks on FFA, and crosses over retinal vessels. When in doubt, refer.
SELF-CHECK
Which of the following is the LEADING CAUSE of visual loss in diabetic retinopathy, even in patients with only non-proliferative disease?
A. Vitreous haemorrhage from ruptured neovessels
B. Tractional retinal detachment
C. Clinically significant macular oedema (CSME) / diabetic macular oedema
D. Optic nerve damage from raised IOP secondary to rubeosis iridis
Reveal Answer
Answer: C. Clinically significant macular oedema (CSME) / diabetic macular oedema
Clinically significant macular oedema (CSME) — also called diabetic macular oedema (DME) — is the leading cause of visual loss in diabetic retinopathy. It can occur at any stage, including in patients with only mild or moderate NPDR, because it involves the fovea directly through leakage from damaged capillaries near the macula. Vitreous haemorrhage and tractional retinal detachment are complications of advanced PDR and cause acute visual loss, but they are less common than CSME as a cause of chronic visual impairment. Rubeosis iridis (new vessels on the iris, causing neovascular glaucoma) is a serious but less frequent complication.
Self-Assessment
Test your mastery of diabetic retinopathy classification and management with these structured questions.
Question 1. A 50-year-old woman with 15-year T2DM has the following fundoscopic findings in her right eye: microaneurysms, several dot-blot haemorrhages in all four quadrants, venous beading in two quadrants, and IRMA in one quadrant. There are no new vessels. What is her retinopathy grade, and what is her risk of progressing to PDR without treatment?
Answer: This is severe NPDR — the 4-2-1 rule is met (haemorrhages in all 4 quadrants, venous beading in 2 quadrants, IRMA in 1 quadrant). Severe NPDR carries approximately 50% risk of progressing to PDR within 12 months. She requires urgent referral to an ophthalmologist for consideration of prophylactic PRP, and systemic optimisation of glycaemic control, blood pressure, and lipids.
Question 2. Why is it wrong to describe 'cotton-wool spots' as a feature of proliferative diabetic retinopathy?
Answer: Cotton-wool spots are ischaemic infarcts of the nerve fibre layer — they represent areas where capillary occlusion has starved a patch of nerve fibres of blood. They are a feature of NPDR, specifically moderate-to-severe NPDR, and result from the same capillary occlusion pathway that eventually leads to PDR. They are not new vessels, do not indicate neovascularisation, and should not be placed under the PDR classification. The defining feature of PDR is neovascularisation (NVD or NVE).
Question 3. A diabetic patient's vision drops suddenly overnight. He describes 'a red curtain across everything.' What has most likely happened, what is the mechanism, and what is the initial management?
Answer: This is almost certainly vitreous haemorrhage — haemorrhage from fragile new vessels (NVD or NVE) of PDR bleeding into the vitreous cavity. The vitreous fills with blood, blocking the visual axis. The 'red curtain' appearance corresponds to seeing through blood. Initial management: urgent ophthalmological referral. If not clearing spontaneously within 3 months, pars plana vitrectomy (PPV) to remove the haemorrhage and allow examination and treatment of the underlying PDR.